The South Korea nebulizer market reached a valuation of approximately USD 62.61 Million in 2025 and is projected to expand at a steady CAGR of 5.40% during the forecast period of 2026 to 2035, ultimately reaching an estimated value of around USD 105.94 Million by 2035. This robust growth is being fueled by the rising prevalence of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), a rapidly ageing population, escalating air pollution levels in metropolitan regions, the surging adoption of homecare-based respiratory therapy, and the rapid integration of smart, IoT-enabled nebulizer technologies into South Korea's tech-forward healthcare ecosystem.

What Is a Nebulizer?

A nebulizer is a medical device that converts liquid medication into a fine mist or aerosol, allowing patients to inhale the drug directly into their lungs. Nebulizers are widely used to treat respiratory conditions such as asthma, COPD, cystic fibrosis, bronchiectasis, and other lung disorders. They are particularly beneficial for young children, elderly patients, and individuals who struggle with conventional inhalers. Available in jet, ultrasonic, and mesh variants, nebulizers are essential tools for both hospital-based and home-based respiratory therapy, offering effective, consistent, and patient-friendly drug delivery.

Why Is the South Korea Nebulizer Market Growing?

The South Korean nebulizer industry is being propelled by a powerful mix of demographic, environmental, and technological factors. South Korea's rapidly ageing population, with a growing share of citizens above 65 years, is creating sustained demand for respiratory care solutions. Worsening urban air quality across Seoul and other metropolitan regions, combined with rising tobacco use and post-pandemic awareness of respiratory health, is significantly driving asthma and COPD incidence. Government-backed initiatives promoting home healthcare, advancements in portable and Bluetooth-enabled smart nebulizers, and improved insurance coverage for chronic respiratory disease management are collectively fueling market expansion.

Request a Free Sample Report to explore detailed market data, segmentation insights, and competitive analysis.

Recent Industry Developments and Updates

The South Korean and global nebulizer landscape has witnessed several notable medical, regulatory, and technological developments shaping the trajectory of the industry:

• March 2024 (Korean Severe Asthma Registry / KoSAR Study): A landmark study by the Korean Severe Asthma Registry found that elderly severe asthma patients aged 65 and above demonstrated lower lung function, higher comorbidity with COPD, and less frequent use of biologics compared to younger patients. The findings strongly reinforce nebulizers as a critical long-term respiratory therapy option for South Korea's ageing population.
• March 2024 (Journal of Korean Medicine Science): A peer-reviewed Korean study revealed that tuberculosis survivors face a 63% higher risk of developing COPD and double the risk of COPD-related hospitalisation, with 9.6% of TB survivors developing COPD. This finding directly drives nebulizer demand across hospitals and homecare settings nationwide.
• June 2024 (FDA Ohtuvayre Approval): The US FDA approved Ohtuvayre (ensifentrine), a nebulizer-compatible dual inhibitor for COPD maintenance therapy, marking the first such approval in over 20 years. This regulatory milestone is expected to significantly expand global nebulization therapy adoption, including in South Korea where COPD prevalence remains high.
• 2024 (Korean Society of Laryngology, Phoniatrics and Logopedics): A Korean clinical study confirmed that nebulization is a safe and effective method for preventing tracheostomy cannula obstruction, even amid prior COVID-era aerosol concerns, validating nebulizer use across hospital-grade and homecare applications.
• May 2024 (WHO Global Asthma Data): The World Health Organization reaffirmed asthma as a major non-communicable disease (NCD) affecting children and elders globally, with airway inflammation symptoms driving sustained nebulizer demand worldwide and across South Korea.
• Smart Nebulizer Adoption Surge: South Korea is witnessing rapid adoption of smart nebulizers featuring Bluetooth-enabled tracking, dose-monitoring systems, IoT integration, AI-driven treatment compliance, and cloud-based remote patient monitoring, aligning with the country's leadership in digital healthcare innovation.
• Vibrating Mesh Nebulizer Innovation: Following HCmed Innovations' launch of Pulmogine (a vibrating mesh nebulizer with Micro Synchronized Delivery Technology) in China (October 2020) and FDA approval (July 2021), similar high-precision mesh devices are gaining strong traction across the South Korean homecare segment.

These developments collectively highlight South Korea's position at the forefront of respiratory care innovation in Asia.

Key Drivers Fueling the South Korea Nebulizer Market Growth

Several converging factors are accelerating market expansion across South Korea:

• Rising Prevalence of Respiratory Disorders: Increasing cases of asthma, COPD, cystic fibrosis, and bronchiectasis are creating sustained nebulizer demand.
• Rapidly Ageing Population: South Korea's elderly population is among the fastest-growing globally, requiring chronic respiratory disease management.
• Worsening Urban Air Quality: Air pollution in Seoul and other metropolitan regions is fueling asthma and COPD prevalence.
• Smart Nebulizer Innovation: Bluetooth, IoT, AI, and cloud-connected devices are transforming respiratory care delivery.
• Homecare Adoption: Growing preference for home-based respiratory therapy is driving demand for portable nebulizers.
• Government Support: Healthcare initiatives and favourable insurance policies covering respiratory devices are encouraging adoption.
• Post-Pandemic Awareness: Heightened public consciousness around respiratory health continues to drive long-term nebulizer adoption.
• Advancements in Inhaled Drug Therapy: New nebulized treatments such as Ohtuvayre are expanding clinical applications.

Are Nebulizers Better Than Inhalers for Respiratory Disease?

Both nebulizers and inhalers are effective drug delivery systems, but nebulizers are particularly advantageous for specific patient groups. Nebulizers convert liquid medication into a fine mist that can be inhaled passively over several minutes, making them ideal for young children, elderly patients, and individuals with severe respiratory conditions who may struggle to coordinate the breathing technique required for metered-dose inhalers. They also enable higher medication doses when needed for acute exacerbations of asthma or COPD. Inhalers, by contrast, are more portable and faster to use, making them suitable for daily maintenance therapy. The choice between the two depends on patient age, severity of condition, and treatment goals as recommended by healthcare professionals.

Emerging Trends Shaping the South Korea Nebulizer Industry

The market is witnessing several transformative trends:

• Smart and IoT-Enabled Nebulizers: Bluetooth tracking, dose-monitoring, and remote patient adherence systems are reshaping respiratory care.
• Vibrating Mesh Technology: Quieter operation, superior drug delivery efficiency, and portability are driving mesh nebulizer adoption.
• Portable and Battery-Powered Devices: Rechargeable, travel-friendly nebulizers are becoming standard for chronic patients.
• Homecare Therapy Expansion: A clear shift from hospital-only to home-based respiratory treatment is underway.
• AI-Driven Treatment Compliance: Cloud-connected platforms enable physicians to monitor patient adherence in real time.
• Pediatric and Geriatric-Friendly Designs: Devices tailored for young children and elderly patients are gaining strong demand.
• Online Pharmacy Distribution Growth: E-commerce channels are emerging as the fastest-growing distribution segment for homecare nebulizers.

South Korea Nebulizer Market Segmentation

The South Korea nebulizer market is comprehensively segmented to provide granular insights into clinical preferences and growth pockets.

Breakup by Type

• Jet
• Ultrasonic
• Mesh
  • Vibrating
  • Piezo-driven
  • Specialized Mesh

Jet nebulizers are expected to dominate the South Korea nebulizer market due to their affordability, widespread availability, and effectiveness in delivering medication for chronic respiratory conditions. Their strong adoption in hospitals and homecare settings is supported by rising asthma and COPD cases across the ageing population. Mesh nebulizers, particularly vibrating and piezo-driven variants, are emerging as the fastest-growing segment due to their quiet operation, portability, and superior aerosol precision.

Breakup by Portability

• Tabletop Nebulizer
• Portable Nebulizer

Portable nebulizers are expected to hold the largest market share, supported by their compact design, growing preference for at-home respiratory care, improved battery life, and rising demand among elderly and chronically ill patients.

Breakup by Application

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Bronchiectasis
• Others

Asthma is expected to lead the application segment due to its high prevalence among Korean children and elders, worsening air quality, and rising allergen exposure. COPD is the fastest-growing application driven by South Korea's ageing population and the elevated risk among tuberculosis survivors.

Breakup by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Hospital pharmacies dominate as the primary distribution channel, supported by trusted healthcare provider associations, high patient demand for severe respiratory conditions, and South Korea's advanced medical infrastructure.

Breakup by End User

• Hospitals and Clinics
• Homecare Settings
• Emergency Centers
• Others

Hospitals and clinics are projected to hold the largest market share, supported by rising hospitalisation rates for respiratory illnesses, advanced nebulisation technology, and trained healthcare professionals across South Korea's leading medical facilities.

Which Region Leads the South Korea Nebulizer Market?

The Seoul Metropolitan Region is poised to lead the South Korea nebulizer market, driven by its advanced healthcare infrastructure, dense concentration of leading hospitals and clinics, high prevalence of respiratory diseases, and growing elderly population. Seoul accounts for a significant share of South Korea's healthcare facilities, including specialized respiratory care institutions and research centers. Rising air pollution levels in the capital region continue to drive sustained demand for nebulizers, while government-backed home healthcare initiatives and the rapid adoption of portable and smart nebulizers further strengthen the region's market dominance. Other key regions include Yeongnam (Southeastern Region), Honam (Southwestern Region), and Hoseo (Central Region).

Competitive Landscape: Leading South Korea Nebulizer Companies

The South Korea nebulizer market features a strong mix of global medical device giants and specialized domestic manufacturers. The comprehensive market report assesses key players using Porter's Five Forces and SWOT analyses, profiling product portfolios, patent activity, grants, funding, and recent strategic developments. The major companies operating in the South Korea nebulizer market include:

Omron Corporation

Omron Corporation, headquartered in Kyoto, Japan, and founded in 1933, is a global leader in healthcare technology expert in medical devices such as nebulizers, blood pressure monitors, and respiratory care solutions. Omron's nebulizers are widely used for treating respiratory conditions, offering innovative mesh and compressor nebulisation technology for efficient drug delivery, supported by strong AI-driven preventive care advancements.

GE HealthCare

GE HealthCare, headquartered in Chicago, United States, and established as an independent company in 2023, is a global medical technology leader expert in medical imaging, patient monitoring, and respiratory care solutions including advanced nebulizers. The company's nebulisation technology integrates precision engineering with innovative aerosol therapy, AI-driven diagnostics, and connected healthcare platforms to enhance patient outcomes globally.

Koninklijke Philips N.V.

Koninklijke Philips N.V., headquartered in Amsterdam, Netherlands, and founded in 1891, is a global leader in healthcare technology offering a diverse portfolio including respiratory care solutions such as nebulizers, oxygen concentrators, and sleep therapy devices. Philips provides high-quality mesh and compressor nebulizers designed for asthma, COPD, and broader respiratory conditions, with a strong focus on patient-centered innovation and homecare expansion.

KTMED INC.

KTMED INC., a leading South Korean medical device manufacturer established in 1995 and headquartered in Gyeonggi-do, specializes in developing high-quality respiratory therapy devices including nebulizers, oxygen therapy equipment, and suction machines. KTMED's nebulizers are recognised for their efficiency, durability, and ease of use, serving both home and clinical settings across South Korea and international markets.

Boditech Med Inc.

Boditech Med Inc., headquartered in Chuncheon, South Korea, is a leading Korean medical diagnostics and device manufacturer specializing in in-vitro diagnostic systems, respiratory care devices, and innovative healthcare technologies. The company plays a strong role in advancing nebulizer technology and respiratory diagnostics across the Korean healthcare system.

Allied Healthcare

Allied Healthcare is a global manufacturer of respiratory care, anesthesia, and emergency medical products, including a comprehensive range of nebulizers, suction units, and oxygen therapy devices. The company supports both hospital-grade and homecare respiratory applications, contributing to advanced nebulisation therapy across global markets including South Korea.

Teleflex Incorporated

Teleflex Incorporated, headquartered in Wayne, Pennsylvania, United States, is a global provider of medical technologies specializing in critical care, surgical, anesthesia, and respiratory care solutions. The company offers a wide range of nebulizers, airway management devices, and aerosol drug delivery systems used across hospitals and emergency care centers worldwide.

Vectura Group Ltd

Vectura Group Ltd, headquartered in Chippenham, United Kingdom, is a leading inhaled drug delivery expert focused on developing nebulizer-compatible drug formulations, smart inhalers, and pulmonary therapeutics. The company collaborates with global pharmaceutical partners to advance innovative nebulised treatments for asthma, COPD, and other respiratory conditions.

DeVilbiss Healthcare LLC.

DeVilbiss Healthcare LLC., headquartered in Somerset, Pennsylvania, United States, is a recognised manufacturer of respiratory care devices including jet nebulizers, oxygen concentrators, suction units, and sleep therapy solutions. The company supplies trusted nebulisation products to hospitals, homecare patients, and clinical settings globally including South Korea.

Other prominent regional and global players are also expanding their footprint in South Korea, contributing to the dynamic and competitive nature of the nebulizer industry.

Frequently Asked Questions (FAQs)

Q1. What was the South Korea nebulizer market size in 2025? The South Korea nebulizer market reached a value of approximately USD 62.61 Million in 2025.

Q2. What is the projected CAGR of the South Korea nebulizer market between 2026 and 2035? The market is expected to grow at a CAGR of 5.40% during the forecast period 2026 to 2035.

Q3. What will the South Korea nebulizer market be worth by 2035? The market is projected to reach approximately USD 105.94 Million by 2035.

Q4. What are the key segments of the South Korea nebulizer market? The market is segmented by type (jet, ultrasonic, mesh including vibrating, piezo-driven, and specialized mesh), portability (tabletop, portable), application (asthma, COPD, cystic fibrosis, bronchiectasis, others), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, others), and end user (hospitals and clinics, homecare settings, emergency centers, others).

Q5. What conditions are nebulizers used to treat? Nebulizers are primarily used to treat asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, and other respiratory disorders. They are particularly beneficial for young children, elderly patients, and individuals with severe respiratory conditions who struggle with conventional inhalers.

Q6. Which region leads the South Korea nebulizer market? The Seoul Metropolitan Region leads the market, supported by advanced healthcare infrastructure, high respiratory disease prevalence, rising air pollution, and a growing elderly population.

Q7. Who are the key players in the South Korea nebulizer market? Major players include Omron Corporation, GE HealthCare, Koninklijke Philips N.V., KTMED INC., Boditech Med Inc., Allied Healthcare, Teleflex Incorporated, Vectura Group Ltd, and DeVilbiss Healthcare LLC., among others.

Q8. What are the latest trends in the South Korea nebulizer industry? Key trends include the rise of smart nebulizers with Bluetooth tracking and dose-monitoring systems, vibrating mesh technology adoption, portable battery-powered devices, AI-driven treatment compliance platforms, and the rapid expansion of homecare-based respiratory therapy.

Q9. What are the major drivers of the South Korea nebulizer market? Major drivers include rising prevalence of asthma and COPD, the rapidly ageing population, worsening urban air quality, smart nebulizer technology adoption, growing homecare adoption, and supportive government healthcare policies.